Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Clinical evidence suggests a 16% reduction in all-cause mortality, highlighting its impact across disease categories
A 72-week trial carried out on Wegovy found that patients using the 7.2 mg maintenance dose achieved, on average, a change in body weight of 21% compared to 2.4% in the placebo group
Cell lysate was then diluted with lysate buffer and divided into two aliquotsone treated with C1-27 (100 M) and the other treated with 1% DMSO
Cared for by our 13-person Los Angeles medical team
References & Sources SURPASS-2 Trial (N Engl J Med) SURMOUNT-1 Trial (N Engl J Med) SELECT Trial Semaglutide CV Outcomes (N Engl J Med) SUMMIT Trial Tirzepatide HFpEF (N Engl J Med) Eli Lilly SURPASS-2 Results (Press Release) Eli Lilly SURMOUNT-1 Results (Press Release) ADA SURPASS Data Presentation SUMMIT Trial ACC Summary SELECT Trial ACC Summary Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
